Afamelanotide - Clinuvel Pharmaceuticals
Alternative Names: [Nle4,DPhe7]-alpha-MSH; Afamelanotide acetate; CUV-1647; EPT-1647; Melanotan I; Melanotan™; MT I; PRENUMBRA; Scenesse; Scenesse® EnfanceLatest Information Update: 10 Apr 2025
At a glance
- Originator University of Arizona
- Developer Clinuvel Pharmaceuticals; Winhealth Pharma
- Class Antiacnes; Antineoplastics; Antipyretics; Melanocyte-stimulating hormones; Peptides; Skin disorder therapies; Vascular disorder therapies
- Mechanism of Action Melanocortin type 1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Erythropoietic protoporphyria
- Phase III Polymorphus light eruptions; Vitiligo
- Phase II Hepatic-porphyria; Ischaemic stroke; Pemphigus; Xeroderma pigmentosum
- Preclinical Parkinson's disease
- Suspended Urticaria
- Discontinued Acne vulgaris; Actinic keratosis; Photodamage; Squamous cell cancer
Most Recent Events
- 26 Mar 2025 Efficacy and adverse events data from a phase II trial in Ischaemic stroke released by Clinuvel Pharmaceuticals
- 26 Mar 2025 Clinuvel Pharmaceuticals completes a phase II CUV803 trial in Ischaemic stroke (In adults, In the elderly) in Spain (SC) (EudraCT2021-006126-52)
- 28 Feb 2025 No recent reports of development identified for phase-I development in Xeroderma-pigmentosum(In volunteers, In adults) in United Kingdom (SC, Implant)